BioMarker Strategies is a Baltimore, MD-based cancer diagnostics company developing the novel SnapPath™ live-tumor-cell biomarker testing system to improve the treatment of cancer.  This automated, patent-pending system is designed to help pathologists and oncologists predict patient response to chemotherapies and targeted cancer therapeutics, reduce unnecessary surgical biopsies and obtain information on treatment options that is not available using current tumor-cell processing methods.

BioMarker Strategies
855 N.Wolfe St., Suite 603
Baltimore, MD 21205

Phone: 410-522-1008
Fax: 410-522-1009
info@biomarkerstrategies.com